KCAT	Mus musculus	0.032	lysophosphatidylcholine	*pH 7.4, temperature not specified in the publication
KCAT	Mus musculus	0.077	1-O-alkyl-sn-glycero-3-phosphocholine	*pH 7.4, temperature not specified in the publication
KM	Mus musculus	0.094	lysophosphatidylcholine	*
KM	Homo sapiens	0.1	lysophosphatidylcholine	*kinetic analysis of recombinant autotaxin/lysoPLD using [14C] lysophosphatidylcholine substrate
KM	Streptomyces chromofuscus	0.15	lysophosphatidylcholine	*
KM	Homo sapiens	0.47	lysophosphatidylcholine	*in presence of 0.25 mM Zn2+ plus 10 mM L-histidine
KM	Homo sapiens	0.47	lysophosphatidylcholine	*in presence of 0.25 mM Zn2+ plus 10 mM L-histidine
KM	Homo sapiens	0.49	lysophosphatidylcholine	*
KM	Homo sapiens	0.49	lysophosphatidylcholine	*
KM	Homo sapiens	0.55	lysophosphatidylcholine	*in presence of 0.25 mM Zn2+
KM	Homo sapiens	0.55	lysophosphatidylcholine	*in presence of 0.25 mM Zn2+
KM	Homo sapiens	0.66	lysophosphatidylcholine	*in presence of 10 mM L-histidine
KM	Homo sapiens	0.66	lysophosphatidylcholine	*in presence of 10 mM L-histidine
KM	Mus musculus	1	lysophosphatidylcholine	*pH 7.4, temperature not specified in the publication
KM	Hemiscorpius lepturus	0.097	1-alkyl-sn-glycero-3-phosphocholine	*pH 7.4, 37&Acirc;&deg;C
KM	Mus musculus	0.32	1-O-alkyl-sn-glycero-3-phosphocholine	*pH 7.4, temperature not specified in the publication
KM	Homo sapiens	0.0026	FS-3	*wild type enzyme, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.0037	FS-3	*
KM	Homo sapiens	0.0063	FS-3	*
KM	Homo sapiens	0.019	FS-3	*mutant enzyme H226Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.069	lysophosphatidylcholine 18:1	*mutant enzyme H420Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.073	lysophosphatidylcholine 18:1	*wild type enzyme, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.105	lysophosphatidylcholine 18:1	*mutant enzyme H434Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.126	lysophosphatidylcholine 18:1	*mutant enzyme H226Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.066	lysophosphatidylcholine 16:0	*wild type enzyme, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.094	lysophosphatidylcholine 16:0	*mutant enzyme H420Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.12	lysophosphatidylcholine 16:0	*mutant enzyme H434Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.126	lysophosphatidylcholine 16:0	*mutant enzyme H226Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.7	4-nitrophenyl-TMP	*wild type enzyme, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	4.8	4-nitrophenyl-TMP	*mutant enzyme H226Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	5.6	4-nitrophenyl-TMP	*
KM	Mus musculus	0.1	1-alkyl-sn-glycero-3-phosphoethanolamine	*achieved under optimal assay conditions, almost same results in blood plasma
KM	Homo sapiens	0.089	lysophosphatidylcholine 18:0	*wild type enzyme, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.115	lysophosphatidylcholine 18:0	*mutant enzyme H420Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.27	lysophosphatidylcholine 18:0	*mutant enzyme H226Q, in 50 mM Tris pH 7.4, 5 mM CaCl2, 1 mg/ml bovine serum albumin, at 37&Acirc;&deg;C
KM	Homo sapiens	0.0031	FS-2	*
KM	Homo sapiens	0.0063	5-[[(23R)-33-(4-[[4-(dimethylamino)phenyl]diazenyl]phenyl)-20,23-dihydroxy-20-oxido-15,33-dioxo-3,6,9,12,19,21,25-heptaoxa-16,32-diaza-20-phosphatritriacont-1-yl]carbamoyl]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid	*
KM	Rattus norvegicus	0.176	1-palmitoyl-glycerophoshorylcholine	*Vmax is 0.3 micromol/min/mg, best substrate
KM	Rattus norvegicus	0.0207	1-palmitoyl-2-lyso-glycerophoshorylcholine	*Vmax is 0.059 micromol/min/mg
KM	Rattus norvegicus	0.101	1-stearoyl-2-lyso-glycerophoshorylcholine	*Vmax is 0.035 micromol/min/mg
KM	Rattus norvegicus	0.0083	1-linoleoyl-2-lyso-glycerophoshorylcholine	*Vmax is 0.019 micromol/min/mg
KM	Rattus norvegicus	0.0267	1-O-hexadecyl-2-lyso-glycerophosphorylcholine	*Vmax is 0.29 micromol/min/mg, lysoPLD activity is more than twice that observed with 1-palmitoyl-glycerophoshorylcholine
KM	Mammalia	0.004	coumarin-phosphate-fluorescein	*coumarin-phosphate-fluorescein is a fluorescence resonance energy transfer (FRET)-based sensor of phosphodiesterase activity. Very useful substrate for enzymatic analysis of purified autotaxin/lysoPLD and can also be used to detect autotaxin/lysoPLD activity in serum-free conditioned culture medium isolated from cells expressing the enzyme
KM	Mammalia	0.004	[5-[[(23S)-33-(4-[(E)-[4-(dimethylamino)phenyl]diazenyl]phenyl)-20,23-dihydroxy-20-oxido-15,26,33-trioxo-3,6,9,12,19,21,25-heptaoxa-16,32-diaza-20-phosphatritriacont-1-yl]carbamoyl]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)phenyl]acetic acid	*[5-[[(23S)-33-(4-[(E)-[4-(dimethylamino)phenyl]diazenyl]phenyl)-20,23-dihydroxy-20-oxido-15,26,33-trioxo-3,6,9,12,19,21,25-heptaoxa-16,32-diaza-20-phosphatritriacont-1-yl]carbamoyl]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)phenyl]acetic acid can be used to detect autotaxin/lysoPLD activity in human and mouse blood
KM	Rattus norvegicus	-999	more	*suggestion that lysoPLD predominantly utilizes saturated forms of lysophosphatidylcholine
KM	Homo sapiens	-999	more	*affinity for lysophosphatidylcholine is significantly higher than for nucleotides
KM	Mus musculus	-999	more	*capable of hydrolyzing sphingosylphosphorylcholine with a significantly higher km-value, also able to hydrolyze nucleotide triphosphates di-adenosine polyphosphates and artificial phosphodiester substrates such as p-nitrophenyl thymidine phosphate with Km-values close to 1 and optimal activity observed at alkaline pH
KM	Homo sapiens	-999	more	*steady-state, single-turnover, and transient kinetics, kinetic analysis and modeling, using artificial fluorescent substrate FS-3, overview
PATH	*	anandamide biosynthesis I	*	*
PATH	*	anandamide biosynthesis II	*	*
PATH	*	Ether lipid metabolism	*	*
PATH	*	plasmalogen degradation	*	*
SA	Rattus norvegicus	-999	*	*nuclear fraction has relatively high levels of lysoPLD activity. Both lysoPLD activity and highest band density found in microsomal fraction
SA	Gallus gallus	-999	*	*lysoPLD activity of diluted or undiluted egg white measured based on enzyme-linked fluorometric measurement of choline produced together with lysophosphatidic acid from exogenous lysophosphatidylcholine. LysoPLD activity measured by determining lysophosphatidic acid and choline by MALDI-TOF-MS, mass spectrometric and enzyme-linked fluorometric analysis. Quantitative analysis of lysophosphatidic acid by MALDI-TOF-MS using a phosphate-capture molecule. Production of lysophosphatidic acid during incubation of hen egg white, changes in the levels of fatty acyl groups
SA	Mus musculus	-999	*	*lysophospholipase D activity is measured by conversion of radiolabeled lysophosphatidylcholine into radiolabeled lysophosphatidic acid
SA	Homo sapiens	-999	*	*lysoPLD activity is assessed, based on the amount of choline released with lysophosphatidylcholine as the substrate, absorption spectrometry. Amounts of the substrate lysophosphatidylcholine and the product lysophosphatidic acid are also checked simultaneously. Changes in the lysoPLD activity and lysophosphatidylcholine and lysophosphatidic acid concentrations in incubated serum. Concentrations of lysophosphatidylcholine and lysophosphatidic acid increase upon incubation, the levels increase significantly as compared with those in the controls (no incubation) after 60-min incubations. Dramatic increase in the lysophosphatidic acid concentration is observed, and the lysophosphatidic acid level after 180-min incubation is about 15times higher than in the control
SA	Bos taurus	-999	*	*Spectrophotometric assay of LysoPLD activity. Determination of lysoPLD activity by measuring the amount of choline released from exogenously added LPC. Fluorometric assay for LysoPLD activity. Determination of LysoPLD activity using a fluorogenic substrate, [5-[[(23S)-33-(4-[(E)-[4-(dimethylamino)phenyl]diazenyl]phenyl)-20,23-dihydroxy-20-oxido-15,26,33-trioxo-3,6,9,12,19,21,25-heptaoxa-16,32-diaza-20-phosphatritriacont-1-yl]carbamoyl]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)phenyl]acetic acid (FS-3)
SA	Mus musculus	-999	*	*To deplete ATX from mouse serum, mouse serum is incubated with the 5E5-Sepharose 4B for 2 h at 4&Acirc;&deg;C, and the resulting supernatant is used for measuring lysoPLD activity and lysophosphatidic acid production. Lysophospholipase D activity of plasma and amniotic fluids isolated from atx+/+ and atx+/-adult mice or atx+/+ and atx+/-embryos at different stages of development measured with immunohistochemistry. LysoPLD activity is determined by liberation of choline from lysophosphatidylcholine using myristyl-lysophosphatidylcholine as a substrate
SA	Homo sapiens	-999	*	*phosphodiesterase activity of recombinant autotaxin is measured by using p-nitrophenyl phenylphosphonate substrate; phosphodiesterase activity of recombinant autotaxin is measured by using p-nitrophenyl phenylphosphonate substrate
SA	Mus musculus	-999	*	*phosphodiesterase activity of recombinant autotaxin is measured by using para-nitrophenyl phenylphosphonate substrate; phosphodiesterase activity of recombinant autotaxin is measured by using p-nitrophenyl phenylphosphonate substrate; phosphodiesterase activity of recombinant autotaxin is measured by using p-nitrophenyl-phenylphosphonate substrate
SA	Homo sapiens	-999	*	*autotaxin/lysoPLD activity is determined at the indicated substrate concentrations using conditioned medium from V5-autotaxin expressing cells as the source of enzyme and radiolabeled lysophosphatidylcholine as substrate
SA	Mammalia	-999	*	*overview of methods for determination of autotaxin/lysoPLD activity. Using radiolabeled substrates and fluorogenic substrates for measuring autotaxin/lysoPLD activity
SA	Homo sapiens	-999	*	*biochemical and cell biological activity of hATX S48 protein measured
SA	Mus musculus	-999	*	*approx. 400 micromol/min/ml, mice are treated with control rat IgG, plasma samples (10 microl) incubate with 4 mmol/l lysophosphatidylcholine, activity determined by enzymatic photometric method using choline oxidase at 560 nm, 37&Acirc;&deg;C; approx. 42 micromol/min/ml, mice are treated with anti-ATX mAb, plasma samples (10 microl) incubate with 4 mmol/l lysophosphatidylcholine, activity determined by enzymatic photometric method using choline oxidase at 560 nm, 37&Acirc;&deg;C
SA	Homo sapiens	-999	*	*approx. 0 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 100fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 0 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 30fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 0 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 1fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 1000 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 100fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 100 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 1fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 104 micromol/ml/min, serum from a patient with severe pre-eclampsia, diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 10 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 30fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 1100 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 100fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 118 micromol/ml/min, serum from a patient with preterm labor (30.1 +/- 0.8 gestational weeks; n is 21), diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 139 micromol/ml/min, serum from a patient with preterm labor (30.1 +/- 0.8 gestational weeks; n is 21), diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 18:2-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 146 micromol/ml/min, serum from a patient with severe pre-eclampsia, diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 18:2-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 150 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 1fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 153 micromol/ml/min, serum from a woman with normal pregnancy (35.8 +/- 0.7 gestational weeks; n is 25), diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 18:2-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 15 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 100fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 15 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 100fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 180 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 1fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 200 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 300 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 350 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 400 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 10fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 450 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 10fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 450 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 10fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 450 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 30fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 49 micromol/ml/min, serum from a patient with moderate pre-eclampsia, diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 18:2-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 500 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 30fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 500 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 30fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx.50 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 10fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 5 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 10fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 60 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 1fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 65 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 10fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 65 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 3.3fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 65 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 1fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 700 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 100fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 80 mmol/ml/min, serum from a patient with severe pre-eclampsia, detection of dilution dependency of choline-producing activity of sera, diluted 3.3fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 8 mmol/ml/min, serum from a patient with preterm labor, detection of dilution dependency of choline-producing activity of sera, diluted 30fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 8 mmol/ml/min, serum from a woman with normal pregnancy, detection of dilution dependency of choline-producing activity of sera, diluted 3.3fold (serum + saline), absence of exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate , 37&Acirc;&deg;C; approx. 90 micromol/ml/min, serum from a woman with normal pregnancy (35.8 +/- 0.7 gestational weeks; n is 25), diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C; approx. 92 micromol/ml/min, serum from a patient with moderate pre-eclampsia, diluted 3.3fold (serum + saline), presence of 0.15 mM exogenous 16:0-lysophosphatidylcholine, radiolabeled substrate, 37&Acirc;&deg;C
SA	Rattus norvegicus	0.000005	*	*depending on presence of divalent cations
SA	Rattus norvegicus	0.00009	*	*lung
SA	Rattus norvegicus	0.0002	*	*testis
SA	Rattus norvegicus	0.00022	*	*liver
SA	Rattus norvegicus	0.00034	*	*kidney
SA	Rattus norvegicus	0.00037	*	*intestine
SA	Oryctolagus cuniculus	0.0027	*	*
SA	Mus musculus	0.0051	*	*Murine autotaxin gamma, p-nitrophenyl phenylphosphonate as a substrate, Vmax 1.8 nmol p-nitrophenyl/min
SA	Homo sapiens	0.00847	*	*human autotaxin alpha, p-nitrophenyl phenylphosphonate as a substrate, Vmax 0.67 nmol p-nitrophenyl/min
SA	Mus musculus	0.0163	*	*Murine autotaxin alpha, p-nitrophenyl phenylphosphonate as a substrate, Vmax 0.35 nanomol p-nitrophenyl/min
SA	Rattus norvegicus	0.036	*	*using isotopic assay
SA	Rattus norvegicus	0.048	*	*colorimetric assay, 6 h incubation, 37&Acirc;&deg;C
SA	Mus musculus	0.0919	*	*Murine autotaxin beta, para-nitrophenyl phenylphosphonate as a substrate, Vmax 1.9 nmol para-nitrophenyl/min
SA	Homo sapiens	0.0997	*	*Human autotaxin gamma, p-nitrophenyl phenylphosphonate as a substrate, Vmax 1.6 nmol p-nitrophenyl/min
SA	Homo sapiens	0.135	*	*Human autotaxin beta, p-nitrophenyl phenylphosphonate as a substrate, Vmax 1.9 nmol p-nitrophenyl/min
SA	Rattus norvegicus	0.14	*	*purified enzyme, HiTrap DEAE FF
